Tarsus Begin Period Cash Flow from 2010 to 2025
| TARS Stock | USD 51.74 1.33 2.51% |
Begin Period Cash Flow | First Reported 2017-12-31 | Previous Quarter 193.7 M | Current Value 181.1 M | Quarterly Volatility 85.9 M |
Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 7.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 32.23, Dividend Yield of 0.0 or PTB Ratio of 2.85. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
Tarsus | Begin Period Cash Flow |
Latest Tarsus Pharmaceuticals' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Tarsus Pharmaceuticals over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Tarsus Pharmaceuticals' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Tarsus Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 40,021,603 | |
| Geometric Mean | 120,684 | |
| Coefficient Of Variation | 150.98 | |
| Mean Deviation | 49,729,004 | |
| Median | 1,000.00 | |
| Standard Deviation | 60,423,884 | |
| Sample Variance | 3651T | |
| Range | 171.3M | |
| R-Value | 0.72 | |
| Mean Square Error | 1911T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 9,076,654 | |
| Total Sum of Squares | 54765.7T |
Tarsus Begin Period Cash Flow History
About Tarsus Pharmaceuticals Financial Statements
Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 82.4 M | 86.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.